• Founded: 2015
  • Location: New York, NY
  • Employee range: 50 - 200
  • Funding: $236M D Feb 2022; $112M C Mar 2020; $21M B Dec 2018; $66M B Feb 2018; $44M A Dec 2015



job board

Short description:

Gut-brain axis focus

Drug notes:

Contact us to add description: recruit@workinbiotech.com

Long description:

Kallyope is exploring the gut-brain axis to discover therapeutics. The gut-brain axis refers to the bi-directional communication between the organs that regulate numerous physiological processes. Many diseases including obesity and diabetes are suspected to be caused by perturbations in the gut-brain axis. By exploring the axis using a systems biology approach and combining the research output with drug discovery expertise, Kallyope is identifying small molecule therapeutics that can restore effective communication. The approach involves Kallyope’s Klarity Platform, an end-to-end process that integrates information from single-cell sequencing, optogenetics, organoids and human genetics with their gut-targeted chemistry of small molecules to build a diverse portfolio of therapies.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com